Q-omics provides the consensus-scored MMAB profile across patient tissues and cancer cell-line models. MMAB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MMAB is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, MMAB RNA expression shows 18,832 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, COAD, and ACC as cancer lineages where MMAB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMAB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMAB survival associations across molecular data types. MMAB RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMAB RNA expression–survival associations across cancer types. High MMAB expression shows unfavorable associations in ACC, MESO and UCS, but favorable associations in SCLC, KIRP and LGG. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for MMAB RNA expression.
This table summarizes MMAB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MMAB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMAB shows lower tumor expression in LUAD, THCA, CHOL and KICH and higher tumor expression in COAD and BLCA. The COAD box plot shows higher MMAB RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with MMAB in patient tissues and cancer cell lines. In patient samples, MMAB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MMAB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
